New Delhi: Aurobindo Pharma Limited on Saturday said its wholly-owned subsidiary, Apitoria Pharma Pvt Ltd, has received a "Voluntary Action Indicated" (VAI) classification from the US health regulator for its API manufacturing facility in Andhra Pradesh.

To advertise here,

A 'VAI' classification means that while objectionable conditions or practices were found during the inspection, the agency is not prepared to take or recommend any administrative or regulatory action.

The United States Food and Drug Administration (USFDA) had inspected Unit-VI of Apitoria Pharma, at Anakapalli district, Andhra Pradesh, from August 24-28, 2026, and concluded with three observations, Aurobindo Pharma said in a regulatory filing.

The unit has now received the Establishment Inspection Report (EIR), classifying the facility as VAI, the company said, adding, "The USFDA has concluded that this inspection is now closed."

(This story has not been edited by Mathrubhumi and is published from a syndicated feed.)